Cell Mol Immunol:杜昌升教授研究组发现G蛋白Gαq参与调控多发性硬化症发生

2017-04-21 佚名 同济大学生命科学与技术学院

近日Cellular & Molecular Immunology(CMI)杂志在线发表同济大学生命科学与技术学院杜昌升教授、交大医学院刘俊岭教授、国家新药筛选中心谢欣教授研究组合作完成的题为“Deficiency of G protein Gαq ameliorates Experimental Autoimmune Encephalomyelitis with impaired DC-

近日Cellular & Molecular Immunology(CMI)杂志在线发表同济大学生命科学与技术学院杜昌升教授、交大医学院刘俊岭教授、国家新药筛选中心谢欣教授研究组合作完成的题为“Deficiency of G protein Gαq ameliorates Experimental Autoimmune Encephalomyelitis with impaired DC-derived IL-6 Production and Th17 Differentiation”的研究论文。本文利用多发性硬化症小鼠模型结合基因敲除的手段,发现G蛋白家族成员Gαq参与调控多发性硬化症小鼠的发病。来自爱尔兰都柏林圣三一学院药学院生理系助理教授Eric J Downer博士同期发文对我们的工作进行了Highlight,认为“The findings certainly place the spotlight on Gαq as the headline act to take to the stage in the development of new GPCR strategies for MS therapy”。

多发性硬化症(Multiple sclerosis,MS)是一种与神经系统相关的自身免疫性炎性疾病。它的特征是免疫调节的中枢神经系统的脱髓鞘和神经退行性病变,临床表现多为视觉障碍、吞咽困难、肌肉无力、忧郁、协调与讲话困难、认知障碍、平衡障碍、体热和疼痛等,发病严重的可导致活动性障碍和残疾。MS的发病机制目前尚不明确。其中普遍认为CD4+ T细胞,尤其是Th1和Th17亚群细胞的过度激活,是导致多发性硬化症发病的重要原因。实验性自身免疫性脑脊髓炎(Experimental autoimmune encephalomyelitis, EAE)是一种多发性硬化症的动物模型,其病理学特征及组织学特征与MS十分相似。

基于小鼠EAE模型的动物实验数据表明许多G蛋白偶联受体(G protein–coupled receptors, GPCRs)在MS发病的多个方面起着至关重要的作用,我们和其他研究组曾报道多个GPCRs参与调控MS/EAE发病,受体药物可以有效抑制疾病的进展。然而作为GPCRs下游的信号转导分子G蛋白在MS/EAE发病过程中的功能却鲜有报道。本项研究发现Gαq敲除小鼠的EAE发病症状相比野生型小鼠明显减轻,进一步研究发现Gαq敲除小鼠外周淋巴组织中致病性的Th17细胞数量明显减少,并且Th17细胞相关特异性表达的基因也呈现出表达量降低的现象。进而我们又探究了TH-17细胞减少的原因,通过体外分化实验发现敲除Gαq能够直接抑制 Th17的分化。同时Gαq也能够通过调控树突状细胞(Dendritic cell,DC)中IL-6的分泌来间接控制Th17的分化。最后我们发现Gαq调控IL-6的分泌是通过Gαq-PLCβ-PKC及Gαq-MAPKs来实现的。本研究为揭示GPCR信号通路在MS发生中的重要作用提供了理论依据,同时将为MS机制研究和疾病治疗提供新的线索。

本研究在杜昌升教授指导下完成。论文的第一作者为来自同济大学的博士研究生赖炜明和蔡盈盈同学。参与此项研究工作的还有研究生周金凤、陈帅、覃朝燕、杨翠霞;以及交大医学院刘俊岭教授、国家新药筛选中心的谢欣教授。同济大学生命科学与技术学院的张儒副教授和医学院的陈小平教授在本项目研究中也提供了指导和帮助。杜昌升研究组一直从事以MS为代表的自身免疫疾病的发病机理解析和诊治新策略的研究,为治疗自身免疫疾病提供新的潜在药物靶点。本研究得到国家重大科学研究计划、国家自然科学基金、上海市教委、及同济大学项目的资助,在同济大学完成。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-07-02 hukaixun
  2. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2018-02-16 jml2009
  5. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-04-27 维他命
  7. [GetPortalCommentsPageByObjectIdResponse(id=2068727, encodeId=38a22068e27a1, content=<a href='/topic/show?id=b17983580d' target=_blank style='color:#2F92EE;'>#Gαq#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8358, encryptionId=b17983580d, topicName=Gαq)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Jul 02 18:09:00 CST 2017, time=2017-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869911, encodeId=1082186991171, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Oct 17 00:09:00 CST 2017, time=2017-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715525, encodeId=cc311e15525fa, content=<a href='/topic/show?id=b1f58362e8' target=_blank style='color:#2F92EE;'>#G蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8362, encryptionId=b1f58362e8, topicName=G蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91a331951491, createdName=12498f1em18(暂无昵称), createdTime=Sun Apr 01 12:09:00 CST 2018, time=2018-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889740, encodeId=cabf1889e4057, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Fri Feb 16 18:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982949, encodeId=4a661982949d1, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Mar 28 22:09:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960170, encodeId=b51119601e0d4, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Apr 27 20:09:00 CST 2017, time=2017-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189567, encodeId=5c0118956e43, content=牛,谢谢分享大牛文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/udqvoAsWtvRVficPKOpMh4M31O9bJ8jMiaUHAheeNpIqMapC8mUnBWfEskrcVjofbicWU4icRD6vFvVeEYlPmSbXELickazEGVFYO/0, createdBy=24741603767, createdName=医艺依意, createdTime=Sat Apr 22 08:00:11 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-04-22 医艺依意

    牛,谢谢分享大牛文章

    0

相关资讯

PNAS:激活G蛋白下游生长因子的细胞渗透肽治疗效果

近日,刊登在国际杂志Proceedings of the National Academy of Sciences上的一篇研究论文中,来自加利福尼亚大学的研究人员在一项概念验证性实验中阐明了可以通过操控细胞交流网络的关键中心来在医学上调节相关的细胞行为,这就使得研究者可以对细胞信号网络中的部分结构进行重编程,而不是靶向作用单一的受体或细胞信号通路。这项基础科学发现的潜在临床价值最终或可帮助开发新型

J Experi Med:G蛋白可以调节血管的重塑过程

2012年11月20日 --近日,刊登在国际杂志Journal of Experimental Medicine上的一篇研究报告中,来自马克斯-普朗克研究所的研究人员揭示了,平滑肌细胞对胞外环境改变做出反应的信号路径的最新研究结果,血管根据其外部的环境会做出动态的变化,其通常会适应营养通透性,收缩性甚至形状可变性。 在这项研究中,研究者对遗传修饰小鼠进行相关研究,试图在细胞水平发现调节血管重塑的

eLife:科学家揭开抑癌又促癌扩散的双刃剑蛋白的神秘面纱

来自加利福尼亚大学的研究人员近日研究发现了一种新型的细胞信号通路,该通路或许可以有效控制结直肠癌的发生和发展,该通路中的一种关键蛋白被认为可以有效预测结直肠癌患者的癌症生存率,相关研究刊登于国际杂志eLife上。 这种特殊蛋白名为“散乱蛋白”,其富含亮氨酸残基或Daple基因,机体中几乎所有的健康细胞都会产生散乱蛋白,而且该蛋白可以帮助不同组织中的细胞来进行多种生物学过程的协调,比如器官发育和维